Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism

Trial Profile

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism

Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2018

At a glance

  • Drugs Rivaroxaban (Primary) ; Acenocoumarol; Enoxaparin sodium; Warfarin
  • Indications Deep vein thrombosis; Pulmonary embolism
  • Focus Registrational; Therapeutic Use
  • Acronyms EINSTEIN-DVT
  • Sponsors Bayer; Bayer HealthCare; Janssen Research & Development
  • Most Recent Events

    • 23 May 2018 Results assessing costs and quality-adjusted life years of DVT patients treated with rivaroxaban or enoxaparin/warfarin in China, presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 12 Dec 2017 Results of exposure-response analysis using patient data from NCT00439777 and NCT00440193 trials presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 29 Oct 2015 Results (n=8245) of this and EINSTEIN-PE trial published in the Thrombosis and Haemostasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top